AddedRisk Factors
intellectual property, we could lose patent protection or the confidentiality of our proprietary information, and possibly also lose the ability to pursue the development of certain new products or product candidates.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
AddedRisk Factors
methods do not infringe the patent claims of the relevant patent and/or that the patent claims are invalid or unenforceable, which we may not be able to do.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
AddedRisk Factors
In December 2025, the European Parliament and the Council of the EU reached a provisional agreement on the revision of the existing EU pharmaceutical legislation, including the pediatric and orphan regulations. Under new legislation, there are some changes to the regulatory exclusivity periods. The provisional agreement is still pending formal approval by the
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
AddedRisk Factors
European Parliament and the Council of the EU and subsequent publication in the Official Journal of the EU. Dependent on the final version of the text, the new legislation could impact our ability to secure orphan designation for future products, and would impact the scope and duration of market and orphan exclusivities in the EU. The new legislation could impact our ability to maintain marketing exclusivity for future products in all EU member states if we are unable to meet certain access obligations or if we are unable to supply sufficient quantities of our product in all member states.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RemovedRisk Factors
Our products compete, and our product candidates may in the future compete, with currently existing therapies, including other branded products, AG and other generic products, product candidates currently under development by us and others and/or future product candidates, including new molecular and chemical entities that may be safer or more effective or more
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedRisk Factors
take longer to realize or cost more than expected, which could materially and adversely affect our business, financial condition, results of operations and growth prospects. In this regard, in the third quarter of 2022, we recorded a $133.6 million asset impairment charge as a result of the decision to discontinue the nabiximols program that we acquired as part of our acquisition of GW. In any event, failure to manage effectively our growth through acquisitions or in-licensing transactions could adversely affect our growth prospects, business, results of operations and financial condition.
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedRisk Factors
Leahy-Smith America Invents Act permits any person, whether they are accused of infringing the patent at issue or not, to challenge the validity of certain patents through a proceeding before the PTAB of the USPTO.
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedRisk Factors
on October 30, 2024, the District Court issued an order denying our motion for summary judgment and granting Avadel’s and FDA’s cross-motions for summary judgment. We have appealed the matter to the United States Court of Appeals for the District of Columbia Circuit. We cannot predict the timing or ultimate outcome of this litigation or the impact of this litigation on our business, including any potential adverse consequences to, among other things, our reputation, relationships with governmental or regulatory authorities, including FDA. For additional information, see "FDA Litigation" in Note 13, Commitments and Contingencies—Legal Proceedings of the Notes to Consolidated Financial Statements, included in Part IV of this Annual Report on Form 10‑K.
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedRisk Factors
product that is similar to a product candidate we are pursuing for the same indication, approval of our product candidate would be blocked during the period of orphan marketing exclusivity unless we could demonstrate that our product candidate is safer, more effective or otherwise clinically superior to the approved product.
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedRisk Factors
If we (or a third party upon whom we rely) experience a security incident or are perceived to have experienced a security incident, or otherwise experience significant disruptions of our, our third party vendors’ and/or business partners’ information technology systems or security breaches, including in our remote work environment, such occurrence could adversely affect our
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedRisk Factors
increase our costs and the complexity of compliance, have been and will continue to be time-consuming to implement, and could have a material adverse effect on our results of operations, particularly if CMS or another agency challenges the approach we take in our implementation. Rebates are no longer subject to a cap on the rebate amount, which negatively impacts our rebate liability.
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedRisk Factors
distribution of our profits or losses between the jurisdictions where we operate and changes to or differences in interpretation of tax laws. For example, our income tax expense for the year ended December 31, 2021, included an expense of $259.9 million arising on the remeasurement of our U.K. net deferred tax liability, which arose primarily in relation to the GW Acquisition, due to a change in the statutory tax rate in the U.K. following enactment of the U.K. Finance Act 2021.
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RewordedRisk Factors
Trade In any event, further trade restrictions and export regulations, or increases in tariffs (including tariffs on imports from Europe) and additional taxes, new or increased tariffs, including any further retaliatory measures, can negatively impact end-user demand, could increase our supply chain complexity and our manufacturing costs, decrease our margins, reduce the competitiveness of our products, or restrict our ability to sell our products, provide services or purchase necessary equipment and supplies, any or all of which could have a material and adverse effect on our business, results of operations, or financial condition and, given the nature of our products, relocating the manufacturing supply can be a complex, costly and time-consuming process making it difficult to react quickly to a changing environment. supplies.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedRisk Factors
For example, the House of Representatives of the prior Congress (the 118th Congress) passed the BIOSECURE Act, which proposed targeting to ban U.S. government contracts, grants grants, and loans for entities that use from being used towards biotechnology equipment and services produced or services from provided by certain named Chinese biotechnology companies, including WuXi, and potentially other would authorize the U.S. government to name additional Chinese biotechnology companies designated in the future. of concern.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedRisk Factors
Although FDA has stated, in granting a Citizen Petition we submitted in 2016, that it would not approve any sodium oxybate ANDA referencing Xyrem that does not include the portions of the currently approved Xyrem label related to the DDI patents, we cannot predict whether a future ANDA filer, or a company that files a Section 505(b)(2) application for a drug referencing Xyrem, may pursue regulatory strategies to avoid infringing our DDI patents notwithstanding FDA’s response to the Citizen Petition, or whether any such strategy would be successful.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedRisk Factors
Regulatory and legislative changes, and judicial rulings relating to the Medicaid Drug Rebate Program and related policies (including coverage expansion), have increased and will continue to increase our costs and the complexity of compliance, have been and will continue to be time-consuming to implement, and could have a material adverse effect on our results of operations, particularly if CMS or another agency challenges the approach we take in our implementation.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedRisk Factors
For example, Similarly, even though FDA also granted seven-year ODE to Xywav, Xywav in IH, FDA also approved Lumryz and granted Lumryz seven-year ODE ODD based on FDA’s finding the plausible hypothesis that Lumryz makes may be clinically superior to Xywav and Xyrem because Lumryz may provide a major contribution to patient care and is therefore clinically superior to Xywav and Xyrem. care.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedRisk Factors
In this regard, our ability to maintain oxybate revenues and realize the anticipated benefits from our investment in Xywav are subject to a number of risks and uncertainties as discussed in greater detail below, including: those related to the commercialization of Xywav for the treatment of IH in adults and adoption in that indication; competition from the introduction of AG versions of high-sodium oxybate and branded products, such as Avadel’s Alkermes’ once-nightly dose, high-sodium oxybate branded product Lumryz, Lumryz (acquired through its acquisition of Avadel), for treatment of cataplexy and/or EDS in adults with narcolepsy in the U.S. market, as well as potential future competition from additional AG and generic versions of high-sodium oxybate, including a generic version of high-sodium oxybate from Amneal approved in September 2025, from Ascent approved in November 2025, and from other competitors; increased pricing pressure from, changes in policies by, or restrictions on reimbursement imposed by, third party payors, including our ability to maintain adequate coverage and reimbursement for Xywav and Xyrem; Xywav; increased rebates required to maintain access to our products; challenges to our intellectual property around Xyrem and/or Xywav, including from pending antitrust and intellectual property litigation; and continued acceptance of Xywav and Xyrem by physicians and patients.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedRisk Factors
A substantial decline in oxybate revenues could cause us to reduce our operating expenses or seek to raise additional funds and would have a material adverse effect on our business, financial condition, results of operations and growth prospects, including on our ability to acquire, in-license or develop new products to grow our business.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedRisk Factors
While a Phase 3 confirmatory trial is ongoing to evaluate zanidatamab in combination with standard-of-care therapy versus standard-of-care therapy alone in the first-line setting for patients with HER2-positive BTC, our inability to confirm its clinical benefit in the first-line setting for patients with HER2-positive BTC could result in the withdrawal of approval of Ziihera, which could have a material adverse effect on our business, financial condition, results of operations and growth prospects.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedRisk Factors
While a the Phase 3 ACTION confirmatory trial is ongoing to evaluate zanidatamab Modeyso in combination with standard-of-care therapy versus standard-of-care therapy alone in the first-line setting for patients with HER2-positive BTC, H3 K27M-mutant diffuse glioma, our inability to confirm its clinical benefit in the first-line setting for patients with HER2-positive BTC diffuse midline glioma harboring an H3 K27M mutation could result in the withdrawal of approval of Ziihera, Modeyso, which could have a material adverse effect on our business, financial condition, results of operations and growth prospects.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedRisk Factors
If there are delays in qualifying new suppliers or facilities or a new supplier is unable to meet FDA’s or similar international regulatory body’s requirements for approval, there could be a shortage of the affected products for the marketplace or for use in clinical studies, or both, which could negatively impact our anticipated revenues and could potentially cause us to breach contractual obligations with customers or to violate local laws requiring us to deliver the product to those in need.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedRisk Factors
For example, Furthermore, FDA granted accelerated approval to Zepzelca Modeyso for relapsed SCLC adult and pediatric patients 1 year of age and older with diffuse midline glioma harboring an H3 K27M mutation with progressive disease following prior therapy based on data from a Phase 2 trial, which approval is contingent upon verification and description of clinical benefit in a post-marketing clinical trial.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedRisk Factors
Moreover, if a dispute arises with our employees, consultants, advisors or partners over the ownership of rights to inventions, including jointly developed intellectual property, we could lose patent protection or the confidentiality of our proprietary information, and possibly also lose the ability to pursue the development of certain new products or product candidates.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
Because patients, consumers and others may not differentiate other high-sodium oxybate products from our sodium oxybate products or differentiate between the different REMS programs, any negative outcomes, including risks to the public, caused by or otherwise related to a separate high-sodium oxybate REMS, could have a significant negative impact in terms of product liability, our reputation and good will, goodwill, public acceptance of Xywav or Xyrem as a treatment for cataplexy and EDS in narcolepsy or Xywav for the treatment of IH, and prescribers’ willingness to prescribe, and patients’ willingness to take, Xywav or Xyrem, any of which could have a material adverse effect on our business.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
We cannot predict the outcome of these or any potential additional lawsuits; however, if the plaintiffs were to be successful in their claims, they may be entitled to injunctive relief or we may be required to pay significant monetary damages, which could have a material adverse effect on our business, financial condition, results of operations and growth prospects.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
These actions, presently primarily directed by executive orders or memoranda from the Office of Management and Budget, may propose policy changes that create additional uncertainty for our business.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
We have periodically increased the price of our products, including Xywav and Xyrem most recently in January 2025, 2026, and there is no guarantee that we will not make similar price adjustments to our products in the future or that price adjustments we have taken or may take in the future will not negatively affect our sales volumes and revenues.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
Although we are not directly generally subject to HIPAA, we could potentially be subject to criminal penalties if we, our affiliates, or our agents knowingly receive individually identifiable health information maintained by a HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
Drug products approved for medical use by FDA that contain cannabis or cannabis extracts may be controlled substances and and, if so, will be rescheduled to Schedules II-V after approval, or, like Epidiolex, removed completely from the schedules by operation of other laws.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
AddedMD&A
Rylaze® (crisantaspase recombinant) A component of a multi-agent chemotherapeutic regimen for the treatment of ALL and LBL, in adults and pediatric patients 1 year or older who have developed hypersensitivity to September 2022 Canada
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
AddedMD&A
prolonged and non-restorative nighttime sleep. An estimated 37,000 people in the U.S. have been diagnosed with IH and are actively seeking healthcare.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
AddedMD&A
Ziihera is a bispecific HER2-directed antibody that binds to two extracellular sites on HER2. Binding of zanidatamab-hrii with HER2 results in internalization leading to a reduction of the receptor on the tumor cell surface. In the U.S., Ziihera was granted accelerated approval by FDA in November 2024 and is indicated for the treatment of adults with previously treated, unresectable or metastatic HER2-positive (IHC3+) BTC, as detected by an FDA-approved test. Ziihera was launched in December 2024. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the Phase 3 HERIZON-BTC-302 confirmatory trial. In June 2025, the EC granted conditional marketing authorization for Ziihera for the treatment of adults with unresectable locally advanced or metastatic HER2-positive (IHC3+) BTC previously treated with at least one prior line of systemic therapy. In January 2026, Ziihera obtained conditional approval in Canada for the treatment of adults with previously treated, unresectable locally advanced or metastatic HER2-positive (IHC3+) BTC, as monotherapy.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
AddedMD&A
We completed the Chimerix Acquisition in April 2025 for a total cash consideration of $944.2 million, adding Modeyso, a protease activator of the ClpP that also inhibits DRD2, to our rare oncology portfolio. In August 2025, Modeyso was granted accelerated approval by FDA for the treatment of adult and pediatric patients 1 year of age and older with diffuse midline glioma harboring an H3 K27M mutation with progressive disease following prior therapy. Modeyso is the first and only treatment option approved by FDA for this ultra-rare and aggressive brain tumor that mainly affects children and young adults. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the Phase 3 ACTION confirmatory trial. In connection with the approval by FDA of Modeyso in August 2025, we received a rare pediatric disease PRV, which we sold in January 2026 for total cash consideration of $200.0 million of which 50% is attributable to us.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
AddedMD&A
stage SCLC whose disease has not progressed after first-line induction therapy with atezolizumab, or atezolizumab and hyaluronidase-tqjs carboplatin and etoposide.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
AddedMD&A
In October 2025, we divested Sativex to CNX Therapeutics, who will assume responsibility for Sativex in all countries it is approved. Our existing partnerships will transition to CNX Therapeutics and it will take responsibility for commercialization in those markets previously owned by us. We will continue to manufacture Sativex during the transition period given the complexity of the product and all external growing partnerships will transition to CNX Therapeutics.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
AddedMD&A
In November 2025, we announced positive top-line results from the pivotal Phase 3 HERIZON-GEA-01 trial of zanidatamab in combination with chemotherapy, with or without tislelizumab, as first-line treatment for adults with HER2-positive locally advanced or metastatic GEA. In January 2026, we presented late-breaking results from the trial at ASCO GI. The investigational arm containing zanidatamab plus tislelizumab and chemotherapy demonstrated a statistically significant and clinically meaningful overall survival benefit of more than two years of median overall survival. The greater than seven-month improvement in median overall survival represents a 28% reduction in the risk of death versus the control arm. Both investigational arms led to a statistically significant and clinically meaningful median progression-free survival of more than one year, representing a greater than four-month improvement and 35% reduction in the risk of disease progression or death
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
AddedMD&A
versus the control arm. FDA granted BTD for zanidatamab's development for patients with HER2+ unresectable locally advanced or metastatic GEA
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
AddedMD&A
Zanidatamab is currently being evaluated in multiple clinical trials as a treatment for patients with HER2-expressing cancers: a Phase 2 DiscovHER-Pan-206 trial evaluating zanidatamab monotherapy in previously-treated patients with various HER2-positive (IHC3+) cancers, a Phase 2 EmpowHER-BC-208 trial to evaluate zanidatamab in patients with HER2-positive neoadjuvant and adjuvant breast cancer, a Phase 3 trial EmpowHER-BC-303 to evaluate zanidatamab plus chemotherapy or trastuzumab plus chemotherapy in patients with HER2-positive breast cancer whose disease has progressed on previous T-DXd treatment, and a Phase 3 confirmatory trial examining zanidatamab in first-line patients with HER2-positive BTC.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
AddedMD&A
In April 2025, we completed the Chimerix Acquisition for $944.2 million in cash, and Chimerix is now our wholly owned subsidiary. The lead clinical asset acquired from Chimerix is Modeyso, a novel first-in-class small molecule that is a protease activator of the ClpP that also inhibits DRD2. In August 2025, Modeyso was granted accelerated approval by FDA for the treatment of adult and pediatric patients 1 year of age and older with diffuse midline glioma harboring an H3 K27M mutation with progressive disease following prior therapy. Modeyso is the first and only treatment option approved by FDA for this ultra-rare and aggressive brain tumor that mainly affects children and young adults. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the Phase 3 ACTION confirmatory trial. The ongoing Phase 3 ACTION trial is evaluating Modeyso in newly diagnosed, non-recurrent H3 K27M-mutant diffuse glioma patients following radiation treatment, potentially extending this treatment option into the front-line setting.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
AddedMD&A
In November 2025, we initiated a Phase 1b trial evaluating Epidiolex as an adjunctive treatment in reducing the frequency of focal seizures compared to the baseline as well as the effect of Epidiolex on health outcome endpoints in early line and refractory participants with focal-onset seizures.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
AddedMD&A
Dordaviprone First-line H3 K27M-mutant diffuse glioma (ACTION trial) (ongoing confirmatory trial)
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RemovedMD&A
Our strategy to deliver sustainable growth and enhanced value continues to be focused on:
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedMD&A
•Strong commercial execution to drive diversified revenue growth and address unmet medical needs of our patients across our product portfolio, which focuses on neuroscience and oncology medicines;
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedMD&A
•Expanding and advancing our pipeline to achieve a valuable portfolio of durable, highly differentiated products;
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedMD&A
•Continuing to build a flexible, efficient and productive development engine for targeted therapeutic areas to identify and progress early-, mid- and late-stage assets;
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedMD&A
•Identifying and acquiring novel product candidates and approved therapies to complement our existing pipeline and commercial portfolio;
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedMD&A
•Investing in an efficient, scalable operating model and differentiated capabilities to enable growth; and
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedMD&A
•Unlocking further value through indication expansion and entry into global markets.
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedMD&A
Ziihera is a bispecific HER2-directed antibody that binds to two extracellular sites on HER2. Binding of zanidatamab-hrii with HER2 results in internalization leading to a reduction of the receptor on the tumor cell surface. In the U.S., Ziihera
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedMD&A
was approved by FDA in November 2024 and is indicated for the treatment of adults with previously treated, unresectable or metastatic HER2-positive (IHC 3+) BTC, as detected by an FDA-approved test.
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedMD&A
Defitelio is the first and only approved treatment for patients with VOD, sVOD, or VOD with renal or pulmonary dysfunction following HSCT by regulatory authorities in the U.S., Europe, Japan and other markets. Utilization of Defitelio is in part driven by evolving treatment practices in HSCT, and we are continuing to educate healthcare professionals on the clinical profile of Defitelio and its role in treating VOD and/or severe VOD following HSCT.
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedMD&A
Vyxeos is a treatment for adults with newly-diagnosed t-AML, or AML-MRC. In March 2021, FDA approved a revised label to include a new indication to treat newly-diagnosed t-AML, or AML-MRC, in pediatric patients aged one year and older. We continue to expand into new markets internationally as the product receives approvals and reimbursement in relevant markets. In the U.S., with ongoing trends towards lower-intensity treatments and away from intensive chemotherapy regimens for AML, we have seen increasing competition from other therapeutic options.
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedMD&A
In addition, we have an ongoing Phase 4 observational study to collect real world safety and outcome data in adult Zepzelca monotherapy patients with SCLC who progress on or after prior platinum-containing chemotherapy. Preliminary findings from this study presented at the 2024 World Conference on Lung Cancer demonstrated Zepzelca provided clinical
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RewordedMD&A
Department of Health and Human Services Secretary to negotiate, with respect to Medicare units and subject to a specified cap, the price of a set number of certain high Medicare spend drugs and biologicals per year starting in 2026, penalizes manufacturers of certain Medicare Parts B and D drugs for price increases above inflation, and makes The IRA also made several changes to the Medicare Part D benefit, including a limit on annual out-of-pocket costs and a change in manufacturer liability under the program, that could negatively affect our business and financial condition.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedMD&A
Department of Health and Human Services For example, the IRA, among other things, requires the HHS Secretary to negotiate, with respect to Medicare units and subject to a specified cap, the price of a set number of certain high Medicare spend drugs and biologicals per year starting in 2026, 2026 and penalizes manufacturers of certain Medicare Parts B and D drugs for price increases above inflation, and makes several changes to the Medicare Part D benefit, including a limit on annual out-of-pocket costs and a change in manufacturer liability under the program, that could negatively affect our business and financial condition. inflation.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedMD&A
Our contingent obligations to third parties, in the form of development, regulatory and sales-based milestone payments, as of December 31, 2024 2025 included $1,362.5 million under our license and collaboration agreement with Zymeworks, $1,255.0 million under our global license and collaboration agreement with Werewolf, $1,090.0 million under our license agreement with Sumitomo, $1,065.0 million under our asset purchase agreements with Redx, $992.5 million under our global license agreement with Saniona, $752.5 million under our license and collaboration agreement with Autifony, $581.0 $531.0 million under our amended license agreement with PharmaMar, $375.0 million under the asset purchase and exclusive license agreement with SpringWorks Therapeutics, Inc., $260.0 million in connection with our acquisition of Cavion, $155.5 million under our license agreement with Ligand, and $492.4 million related to other agreements.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedMD&A
If we are unable to obtain further share issuance and pre-emption authorities from our shareholders in the future, or otherwise continue to be limited by the terms of new share issuance and pre-emption authorities approved by our shareholders in the future, our ability to use our unissued share capital to fund in-licensing, acquisition or other business opportunities, or to otherwise raise capital, including at the time we are required to make repurchases of the 2026 Notes, the 2030 Notes and/or the Secured Notes, are required to repay outstanding amounts under the Amended Credit Agreement, or pay cash upon exchange of the 2026 Notes or the 2030 Notes, could likewise be adversely affected.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedMD&A
For 2025, 2026, we expect that our research and development R&D expenses will decrease increase compared to 2024, 2025, primarily driven by a reduction an increase in clinical studies and outside services service costs relating to JZP385 zanidatamab, for both ongoing and continued portfolio prioritization. new studies, dordaviprone, due to the inclusion of a full year’s expenses, and preclinical and early clinical programs.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedMD&A
In May 2022, we announced that we had entered into a licensing agreement with Sumitomo to acquire exclusive development and commercialization rights in the U.S., Europe and other territories for JZP441, also known as DSP-0187, JZP441 is a potent, highly selective oral orexin-2 receptor agonist with potential application for the treatment of narcolepsy, IH and other sleep disorders.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedMD&A
We Under these amendments, we continue to have the right to receive a meaningful royalty from Hikma on net sales of the Hikma AG product; product throughout the extended Hikma AG period, which royalty rate was fixed for through the second half end of 2023. 2025 and then subject to specified reductions as set forth in our agreement with Hikma.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedMD&A
The holders of the 2030 Notes have the ability to require us to repurchase all or a portion of their 2030 Notes for cash at a fundamental change repurchase price equal to 100% of the principal amount of the notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date in the event we undergo a fundamental change (as defined in the indenture related to the 2030 Notes), such as specified change of control transactions, our liquidation or dissolution or the delisting of our ordinary shares from any of The New York Stock Exchange, The Nasdaq Global Market, The Nasdaq Global Select Market or The Nasdaq Capital Market (or any of their respective successors).
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedMD&A
In April 2022, August 2025, we announced that we had entered into a licensing and collaboration global license agreement with Werewolf Saniona to acquire obtain exclusive global development and commercialization worldwide rights to Werewolf's investigational WTX-613, develop SAN2355, now referred to as JZP898. JZP053, for epilepsy and other potential indications.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedMD&A
Our commercial efforts are focused on educating patients and physicians about on the lifelong impact strength of high sodium intake, and how clinical evidence that supports the use of Xywav enables them to address what is a modifiable risk factor for cardiovascular morbidity. treating narcolepsy and IH.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedMD&A
Xywav Vyxeos product sales increased by 10% in 2024 compared to 2023, primarily due to increased sales volumes of 16% and, to a lesser extent, a higher selling price, volumes, partially offset by higher gross a lower average selling price due to net deductions. regional mix.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedMD&A
These You should review the risks and uncertainties described in “Risk Factors” in Part I, Item 1A in this Annual Report on Form 10‑K for a discussion of important factors that could cause actual results to differ materially from those projected in forward-looking statements contained in this report or implied by past results and trends.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
Quiet changesMD&A
FDA also approved the expansion of all existing the other indications, LGS and DS, to patients one year of age and older.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
Quiet changesMD&A
AG products will be are distributed through the same REMS as Xywav and Xyrem.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
Quiet changesMD&A
We cannot predict the outcome of these or any potential additional lawsuits; however, if the plaintiffs were to be successful in their claims against us, they may be entitled to injunctive relief or we may be required to pay significant monetary damages.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
Quiet changesMD&A
Cost of product sales increased in 2024 compared to 2023, primarily due to increased inventory provisions and changes in product mix, offset by a decrease in the fair value step-up expense, of $16.4 million.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
Quiet changesMD&A
Finite-lived intangible assets consist primarily of purchased developed technology and are amortized on a straight-line basis over their estimated useful lives, which range from seven four to sixteen years.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new